Assembly Biosciences (ASMB) Non-Current Deffered Revenue (2017 - 2025)

Assembly Biosciences' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $1.7 million for Q3 2025.

• On a quarterly basis, Non-Current Deffered Revenue fell 94.72% year-over-year to $1.7 million in Q3 2025; TTM through Sep 2025 was $1.7 million, a 94.72% decrease from a year earlier, with the FY2024 full-year figure at $35.4 million, down 36.12% from the prior year.
• Non-Current Deffered Revenue eased to $1.7 million in Q3 2025 per ASMB's latest filing, from $13.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $55.4 million in Q4 2023 and bottomed at $1.7 million in Q3 2025.
• The 5-year median for Non-Current Deffered Revenue is $2.7 million (2021), against an average of $13.9 million.
• Across the five-year window, Non-Current Deffered Revenue soared 1926.31% in 2023 and plunged 94.72% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $2.7 million in 2021, then changed by 0.0% to $2.7 million in 2022, then surged by 1926.31% to $55.4 million in 2023, then plunged by 36.12% to $35.4 million in 2024, then slumped by 95.15% to $1.7 million in 2025.
• Per Business Quant, the three latest ASMB Non-Current Deffered Revenue figures stand at $1.7 million (Q3 2025), $13.0 million (Q2 2025), and $22.8 million (Q1 2025).